An interventional study of vaccination game in HPV and Vaccine-Preventable Diseases, sponsored by Michigan State University. Recruiting at 1 site in United States. Open to participants aged 11 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-20.
Sponsored by Michigan State University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Vaccine-Preventable Diseases with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Vaccine-Preventable Diseases · United States.
Among the 16 studies in Vaccine-Preventable Diseases with a site in United States, this one is the 7th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 11 with no phase, and was the 9th registered.
53 studies on the registry are indexed under Vaccine-Preventable Diseases; 12 are open to participants now.
Browse Vaccine-Preventable Diseases studies →1 of the 16 studies in Vaccine-Preventable Diseases with a site in United States is open now.
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Vaccine-Preventable Diseases studies recruiting now, 2 set no upper age limit and 6 stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 11 Years to 14 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 180 is close to the median of 190 across 42 interventional studies indexed under Vaccine-Preventable Diseases.
Median enrollment 133 across the 15 interventional studies, 71 across the 1 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
Michigan State University is the lead sponsor of 143 studies on the registry; 27 are open to participants now.
Michigan State University has 2 studies filed under Vaccine-Preventable Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Vaccine-Preventable Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05984849Michigan State UniversityPlaying Game to Learn About Children's Vaccine Project | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Vaccine-Preventable Diseases with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This proposed study aims to conduct timely research that promotes vaccine confidence and vaccination of one strongly recommended vaccine with suboptimal uptake rates: Human papillomavirus (HPV) in vulnerable and underserved youth aged 11-14.
The study objectives are:
Objective 1: Assess feasibility (participation rate, retention, involvement, satisfaction) of one game-based interventions targeting HPV vaccination.
Objective 2: Conduct a pilot RCT with three conditions (Arm 1: HPV game-based intervention; Arm 2: usual care). The investigators will explore patterns of pre- to post-intervention change in theoretical mediators and vaccine intent, and explore levels of vaccine intent and uptake in 90 parent-child dyads of unvaccinated youth aged 11-14.
Inclusion Criteria:
Exclusion Criteria: Individuals who do not meet inclusion criteria or refuse to provide consent/assent.
parent-child dyads receive HPV game intervention
Behavioral: vaccination game
parent-child dyads receive usual care (no intervention)
A health game to promote HPV vaccination among youth
Percentage of eligible individuals agreeing to participate
Assessed by the % of eligible individuals agreeing to participate
Time frame: T0 (occurs after consenting and before assigning to different study conditions)
Proportion of participants who are retained through follow-up
Assessed by the % of participants who are retained through follow-up
Time frame: T2 (occurs two months after completion of the intervention)
Percentage of participants who complete the intervention and assessments
Assessed by the % of participants who complete the intervention and assessments
Time frame: T2 (occurs two months after completion of the intervention)
Participant satisfaction with the project
Assessed by two Likert scale questions: (1) are you satisfied with the program? (2) Will you recommend this program to others? Responses: from (1) very dissatisfied/definitely not to (5) very satisfied/definitely yes)
Time frame: T2 (occurs two months after completion of the intervention)
Intention to vaccinate the children against HPV
Assessed by a Likert scale question: How likely will you (parent) vaccinate your child against HPV? Responses: (0) no; (1) maybe; (2) yes
Time frame: T0 (occurs after consenting and before assigning to different study conditions); T1 (occurs immediately post intervention);T2 (occurs two months after completion of the intervention)
Children receives the first dose of HPV vaccine
Assessed by one binary question regarding whether or not the child has received the first dose of HPV vaccine. Responses: yes, no
Time frame: T2 (occurs two months after completion of the intervention)
Plan to share: Yes — De-identified, non-sensitive data will be deposited in Dryad no later than the date of publication.
Time frame: Start: no later than the date of publication End: remain publicly available for 3 years following publication
Access criteria: All users will have open access to the data without restriction, consistent with Dryad's open-access model. Data can be accessed directly through Dryad's website using the assigned DOI, ensuring discoverability and persistent availability. No personally identifiable or sensitive information will be shared.
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.
Of 17 interventional studies with no phase under Vaccine-Preventable Diseases, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 20 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vaccine-Preventable Diseases →